Actively Recruiting
sCD163 in PBC Patients - Assessment of Treatment Response
Led by University of Aarhus · Updated on 2022-08-12
40
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.
CONDITIONS
Official Title
sCD163 in PBC Patients - Assessment of Treatment Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed with Primary biliary cholangitis
- No treatment with UDCA
You will not qualify if you...
- Patient under 18 years
- Expected lifetime under 6 months
- Expected liver transplantation within 6 months
- Liver cancer
- Cirrhosis from other causes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
Aarhus C, Central Jutland, Denmark, 8000
Actively Recruiting
Research Team
L
Lars Bossen, PhD-student
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here